Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.
Alig AHS, Modest DP, Stintzing S, Heinrich K, Geissler M, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Held S, Moosmann N, Stahler A, Tannapfel A, Giessen-Jung C, Jung A, Weiss L, Heinemann V. Alig AHS, et al. Among authors: giessen jung c. ESMO Open. 2024 Sep;9(9):103677. doi: 10.1016/j.esmoop.2024.103677. Epub 2024 Aug 21. ESMO Open. 2024. PMID: 39173562 Free PMC article.
ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?
Aghamaliyev U, Karimbayli J, Giessen-Jung C, Matthias I, Unger K, Andrade D, Hofmann FO, Weniger M, Angele MK, Benedikt Westphalen C, Werner J, Renz BW. Aghamaliyev U, et al. Among authors: giessen jung c. Eur J Cancer. 2024 Jul;205:114100. doi: 10.1016/j.ejca.2024.114100. Epub 2024 May 7. Eur J Cancer. 2024. PMID: 38729055 Free article.
COVID-19 in Patients with Active Cancer: Higher Inflammatory Activity Predicts Poor Outcome.
Rüthrich MM, Khodamoradi Y, Lanznaster J, Stecher M, Tometten L, Voit F, Koll CEM, Borgmann S, Vehreschild JJ, Ole Jensen BE, Hanses F, Giessen-Jung C, Wille K, von Lilienfeld-Toal M, Beutel G; LEOSS Study Group. Rüthrich MM, et al. Among authors: giessen jung c. Oncol Res Treat. 2024;47(3):88-96. doi: 10.1159/000535267. Epub 2023 Nov 15. Oncol Res Treat. 2024. PMID: 37967545 Free article.
Early clinical trial unit tumor board: a real-world experience in a national cancer network.
Weiss L, Dorman K, Boukovala M, Schwinghammer F, Jordan P, Fey T, Hasselmann K, Subklewe M, Bücklein V, Bargou R, Goebeler M, Sayehli C, Spoerl S, Lüke F, Heudobler D, Claus R, von Luettichau I, Lorenzen S, Lange S, Westphalen CB, von Bergwelt-Baildon M, Heinemann V, Gießen-Jung C. Weiss L, et al. Among authors: giessen jung c. J Cancer Res Clin Oncol. 2023 Nov;149(14):13383-13390. doi: 10.1007/s00432-023-05196-x. Epub 2023 Jul 25. J Cancer Res Clin Oncol. 2023. PMID: 37490102 Free PMC article.
Analysis of Circulating Immune Subsets in Primary Colorectal Cancer.
Lu C, Schardey J, Wirth U, von Ehrlich-Treuenstätt V, Neumann J, Gießen-Jung C, Werner J, Bazhin AV, Kühn F. Lu C, et al. Among authors: giessen jung c. Cancers (Basel). 2022 Dec 12;14(24):6105. doi: 10.3390/cancers14246105. Cancers (Basel). 2022. PMID: 36551592 Free PMC article.
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
Stahler A, Modest DP, Fischer von Weikersthal L, Kaiser F, Decker T, Held S, Graeven U, Schwaner I, Denzlinger C, Schenk M, Kurreck A, Heinrich K, Gießen-Jung C, Neumann J, Kirchner T, Jung A, Stintzing S, Heinemann V. Stahler A, et al. Among authors: giessen jung c. Eur J Cancer. 2022 Sep;173:194-203. doi: 10.1016/j.ejca.2022.06.019. Epub 2022 Aug 5. Eur J Cancer. 2022. PMID: 35940054
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE, Stintzing S, von Weikersthal LF, Modest DP, Decker T, Kiani A, Kaiser F, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Giessen-Jung C, Uhlig J, Peuser B, Denzlinger C, Stahler A, Weiss L, Heinrich K, Held S, Jung A, Kirchner T, Heinemann V. Fischer LE, et al. Among authors: giessen jung c. Br J Cancer. 2022 Sep;127(5):836-843. doi: 10.1038/s41416-022-01854-y. Epub 2022 May 30. Br J Cancer. 2022. PMID: 35637412 Free PMC article. Clinical Trial.
38 results